Cargando…

Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer

BACKGROUND: Accumulating evidence shows that microRNAs are aberrantly expressed and exert essential roles in the tumorigenesis and tumor progression of non‐small cell lung cancer (NSCLC). METHODS: The plasma miRNAs from five healthy donors and four NSCLC patients were profiled by miRNA microarray. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Xiaohan, Chang, Minghui, Song, Xingguo, Ding, Shanshan, Xie, Li, Song, Xianrang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882392/
https://www.ncbi.nlm.nih.gov/pubmed/33372399
http://dx.doi.org/10.1111/1759-7714.13800
_version_ 1783651037403414528
author Dong, Xiaohan
Chang, Minghui
Song, Xingguo
Ding, Shanshan
Xie, Li
Song, Xianrang
author_facet Dong, Xiaohan
Chang, Minghui
Song, Xingguo
Ding, Shanshan
Xie, Li
Song, Xianrang
author_sort Dong, Xiaohan
collection PubMed
description BACKGROUND: Accumulating evidence shows that microRNAs are aberrantly expressed and exert essential roles in the tumorigenesis and tumor progression of non‐small cell lung cancer (NSCLC). METHODS: The plasma miRNAs from five healthy donors and four NSCLC patients were profiled by miRNA microarray. The differentially expressed miRNAs from 154 primary NSCLC patients and 146 healthy donors were subjected to RNA isolation and verified by quantitative PCR (qPCR). RESULTS: The miRNA microarray analysis revealed that 40 differential miRNAs between NSCLC patients and healthy donors were selected. We found that the plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p levels of patients were significantly higher than those of healthy controls. The receiver operating characteristic curve (ROC) analyses revealed higher area under the ROC curve (AUC) values and higher sensitivity/specificity of carcinoembryonic antigen (CEA) in combination with miR‐1247‐5p, miR‐301b‐3p, or miR‐105‐5p were superior to that of CEA alone. CONCLUSIONS: High miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p expression have been demonstrated to accelerate tumorigenesis, and these three miRNAs in plasma act as novel biomarkers for the early diagnosis of NSCLC patients. KEY POINTS: Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p act as novel biomarkers for early NSCLC and NSCLC.
format Online
Article
Text
id pubmed-7882392
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-78823922021-02-19 Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer Dong, Xiaohan Chang, Minghui Song, Xingguo Ding, Shanshan Xie, Li Song, Xianrang Thorac Cancer Original Articles BACKGROUND: Accumulating evidence shows that microRNAs are aberrantly expressed and exert essential roles in the tumorigenesis and tumor progression of non‐small cell lung cancer (NSCLC). METHODS: The plasma miRNAs from five healthy donors and four NSCLC patients were profiled by miRNA microarray. The differentially expressed miRNAs from 154 primary NSCLC patients and 146 healthy donors were subjected to RNA isolation and verified by quantitative PCR (qPCR). RESULTS: The miRNA microarray analysis revealed that 40 differential miRNAs between NSCLC patients and healthy donors were selected. We found that the plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p levels of patients were significantly higher than those of healthy controls. The receiver operating characteristic curve (ROC) analyses revealed higher area under the ROC curve (AUC) values and higher sensitivity/specificity of carcinoembryonic antigen (CEA) in combination with miR‐1247‐5p, miR‐301b‐3p, or miR‐105‐5p were superior to that of CEA alone. CONCLUSIONS: High miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p expression have been demonstrated to accelerate tumorigenesis, and these three miRNAs in plasma act as novel biomarkers for the early diagnosis of NSCLC patients. KEY POINTS: Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p act as novel biomarkers for early NSCLC and NSCLC. John Wiley & Sons Australia, Ltd 2020-12-28 2021-02 /pmc/articles/PMC7882392/ /pubmed/33372399 http://dx.doi.org/10.1111/1759-7714.13800 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Dong, Xiaohan
Chang, Minghui
Song, Xingguo
Ding, Shanshan
Xie, Li
Song, Xianrang
Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
title Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
title_full Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
title_fullStr Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
title_full_unstemmed Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
title_short Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
title_sort plasma mir‐1247‐5p, mir‐301b‐3p and mir‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882392/
https://www.ncbi.nlm.nih.gov/pubmed/33372399
http://dx.doi.org/10.1111/1759-7714.13800
work_keys_str_mv AT dongxiaohan plasmamir12475pmir301b3pandmir1055paspotentialbiomarkersforearlydiagnosisofnonsmallcelllungcancer
AT changminghui plasmamir12475pmir301b3pandmir1055paspotentialbiomarkersforearlydiagnosisofnonsmallcelllungcancer
AT songxingguo plasmamir12475pmir301b3pandmir1055paspotentialbiomarkersforearlydiagnosisofnonsmallcelllungcancer
AT dingshanshan plasmamir12475pmir301b3pandmir1055paspotentialbiomarkersforearlydiagnosisofnonsmallcelllungcancer
AT xieli plasmamir12475pmir301b3pandmir1055paspotentialbiomarkersforearlydiagnosisofnonsmallcelllungcancer
AT songxianrang plasmamir12475pmir301b3pandmir1055paspotentialbiomarkersforearlydiagnosisofnonsmallcelllungcancer